Trends in Cancer

Papers
(The H4-Index of Trends in Cancer is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Revumenib: a new era in acute leukemia treatment265
Tumor-resident microbes: the new kids on the microenvironment block261
Platelets: tailoring metastasis treatment238
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis236
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy209
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology206
Subscription & copyright page205
Spliced to kill: RNA mis-splicing derived cancer neoantigens190
FBXW10: a male-biased E3 ligase in liver cancer190
Advancements in organoid models emulating metastatic niches181
Engineering growth factor ligands and receptors for therapeutic innovation180
Navigating life as an early career researcher175
Leveraging circulating microbial DNA for early cancer detection163
Onco-condensates: formation, multi-component organization, and biological functions162
Subscription and copyright page154
Advisory Board and Contents154
Subscription & copyright page142
Accessing the vasculature in cancer: revising an old hallmark136
Engine shutdown: migrastatic strategies and prevention of metastases133
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer121
Neural hijacking in cancer metabolism: from nutrients to organelles113
Subscription & copyright page112
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology103
FGFR rearrangements: oncogenic drivers and therapeutic targets102
Oncogenic competence: balancing mutations, cellular state, and microenvironment100
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers99
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers98
GOT2 consider the tumor microenvironment97
Advancements in combining targeted therapy and immunotherapy for colorectal cancer93
Recent developments in myeloid immune modulation in cancer therapy92
Gut microbiota – a double-edged sword in cancer immunotherapy86
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?81
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis80
From prediction to precision: how immunopeptidomics advances neoantigen discovery80
Benefits and opportunities of the transgenic Oncopig cancer model77
The evolving landscape of brain metastasis: volume II74
Crosstalk of T cells within the ovarian cancer microenvironment74
Diet, nutrient supply, and tumor immune responses74
Cell death, therapeutics, and the immune response in cancer72
Chromatin as an old and new anticancer target71
Advisory Board and Contents68
Regulation of metastatic organotropism68
Subscription & copyright page67
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation66
Organellar pH as an emerging vulnerability to exploit in cancer64
Genetic immune escape in cancer: timing and implications for treatment62
Toward mutational epidemiology: using mutational signatures of environmental exposures to assess cancer risk62
Planning for cancer: building accessible and high-quality survivorship care for all62
Palmitate paves the way to lung metastasis62
The emerging field of oncolytic virus-based cancer immunotherapy60
Insights on ErbB glycosylation – contributions to precision oncology60
Scaling data toward pan-cancer foundation models60
Clinical and translational relevance of intratumor heterogeneity59
Inflammation: the incubator of the tumor microenvironment58
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence58
Subscription & copyright page56
0.15641403198242